Compass Pathways’ (CMPS) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Compass Pathways (NASDAQ:CMPS) in a research note issued to investors on Monday morning,Benzinga reports. BTIG Research currently has a $14.00 price objective on the stock.

A number of other brokerages have also recently commented on CMPS. Compass Point set a $15.00 target price on shares of Compass Pathways in a research report on Thursday, February 12th. Morgan Stanley lowered their price target on shares of Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. HC Wainwright upped their price objective on shares of Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Finally, Canaccord Genuity Group decreased their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus target price of $21.63.

Compass Pathways Stock Up 42.0%

Shares of CMPS opened at $9.46 on Monday. The stock has a 50 day moving average price of $6.43 and a 200 day moving average price of $6.38. Compass Pathways has a one year low of $2.25 and a one year high of $10.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.06 and a beta of 2.01.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). Equities research analysts forecast that Compass Pathways will post -1.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd acquired a new position in shares of Compass Pathways during the 4th quarter valued at about $38,000. Advisory Services Network LLC acquired a new stake in Compass Pathways during the third quarter worth about $41,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the fourth quarter worth about $47,000. BIT Capital GmbH purchased a new position in Compass Pathways during the third quarter worth about $54,000. Finally, Northeast Financial Consultants Inc acquired a new position in Compass Pathways in the 2nd quarter valued at about $59,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Key Headlines Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: White House executive order to accelerate psychedelics research and access — reduces regulatory timeline risk and prompted renewed investor interest in psilocybin developers like Compass. How Trump’s psychedelics executive order could unlock stalled cannabis reform
• Positive Sentiment: Clinical/FDA momentum: recent press coverage highlights Compass’s Phase 3 wins and filing momentum for its COMP360 psilocybin program, supporting a clearer path toward regulatory filings. Why COMPASS Pathways (CMPS) Is Up 15.4% After Psilocybin Phase 3 Wins And FDA Filing Momentum
• Positive Sentiment: Short‑squeeze/market dynamics amplified the rally — analysts and commentary note high short interest in the name, which accelerated buying after the policy news. This 4/20, Wall Street Is Betting on More Than Marijuana
• Positive Sentiment: Broker support: BTIG reaffirmed a buy rating with a $14 price target (noted coverage via Benzinga), giving an analyst upside narrative for the stock. Benzinga report on BTIG rating
• Positive Sentiment: Unusually large options activity — a spike in call buying (5,436 calls, ~77% above typical volume) signals speculative positioning and conviction by traders ahead of further catalysts.
• Neutral Sentiment: Investor outreach/visibility: CEO Kabir Nath will speak at the Needham Virtual Psychedelics Forum (April 27), offering additional investor updates and program clarity. Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
• Neutral Sentiment: Broader media coverage (Bloomberg, CNN, MSN) is amplifying the story and drawing retail/institutional attention, which can sustain higher intraday volume. Stock Movers: Eli Lilly, Compass Pathways, Fermi
• Negative Sentiment: Fundamental risks remain — Compass reported an earnings miss in March and is a pre‑revenue, cash‑burning biotech with negative EPS; ultimate value depends on regulatory approvals, successful commercialization and execution. (Keep an eye on dilution risk and future financing needs.)

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.